Purchase this article with an account.
Uwe Pleyer, Matthias Klamann, Sibylle Winterhalter, Stephan R. Thurau; Ozurdex: A new therapeutic option in uveitis - Clinical outcome from two German uveitis centers. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2249.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report the experience of two German uveitis centers with a dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex TM; Allergan, Inc, Irvine, CA) in noninfectious posterior uveitis.
The study included 58 eyes with noninfectious uveitis receiving one or more intravitreal injections of a commercially available dexamethasone implant (s), Ozurdex TM. Main outcome measures: Complete ophthalmic examination including signs of inflammatory activity, visual acuity, optical coherence tomography and adverse effects and tolerability of the implant were assessed.
Fifty eight eyes of 48 consecutive patients treated with a total of 63 dexamethasone 0.7 mg sustained-release intravitreal implants for posterior noninfectious uveitis were included. Patients presented with unilateral (n=13) or bilateral posterior/intermediate uveitis (n=45). All eyes showed clinical and morphological evidence of decreased inflammation following implant placement. Maximum clearance of vitreous haze could be achieved within 4 weeks in 82% of all treated eyes (p<0.01), whereas significant reduction (p<0.05) of central retinal thickness was reached at 3 months. Within the mean follow-up of 8.8 months increased IOP (+ 5mmHg) was observed in 43 % of all eyes and reached 35mmHg or above in 12% of all patients. All events of ocular hypertension could be controlled with conservative treatment. No serious ocular or systemic adverse events were noted during the follow-up period.
In patients with noninfectious posterior/intermediate uveitis, the sustained-release dexamethasone 0.7 mg intravitreal implant is an effective treatment option for controlling intraocular inflammation.
This PDF is available to Subscribers Only